ACADIA Pharmaceuticals (ACAD) Scheduled to Post Quarterly Earnings on Wednesday

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) is scheduled to be releasing its earnings data after the market closes on Wednesday, November 6th. Analysts expect ACADIA Pharmaceuticals to post earnings of $0.11 per share for the quarter. ACADIA Pharmaceuticals has set its FY 2024 guidance at EPS.Parties interested in participating in the company's conference call can do so using this link.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last posted its earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.20 earnings per share for the quarter, beating the consensus estimate of $0.18 by $0.02. ACADIA Pharmaceuticals had a net margin of 3.43% and a return on equity of 6.89%. The company had revenue of $241.96 million during the quarter, compared to analysts' expectations of $235.95 million. During the same period last year, the company posted $0.01 earnings per share. ACADIA Pharmaceuticals's quarterly revenue was up 46.4% on a year-over-year basis. On average, analysts expect ACADIA Pharmaceuticals to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

ACADIA Pharmaceuticals Stock Performance

Shares of ACAD traded down $0.04 during midday trading on Wednesday, hitting $14.70. 477,479 shares of the company traded hands, compared to its average volume of 1,678,521. The stock has a market cap of $2.43 billion, a price-to-earnings ratio of -1,474.00, a PEG ratio of 0.49 and a beta of 0.38. The firm has a 50 day moving average of $15.52 and a 200-day moving average of $16.04. ACADIA Pharmaceuticals has a 52 week low of $14.15 and a 52 week high of $32.59.

Analyst Upgrades and Downgrades

ACAD has been the subject of several research reports. UBS Group lowered their price objective on shares of ACADIA Pharmaceuticals from $25.00 to $23.00 and set a "buy" rating for the company in a research report on Thursday, August 8th. StockNews.com upgraded ACADIA Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Friday, September 13th. Raymond James restated a "market perform" rating on shares of ACADIA Pharmaceuticals in a report on Thursday, October 10th. HC Wainwright reissued a "buy" rating and set a $27.00 target price on shares of ACADIA Pharmaceuticals in a research note on Thursday, August 8th. Finally, Morgan Stanley downgraded ACADIA Pharmaceuticals from an "overweight" rating to an "equal weight" rating and decreased their price objective for the company from $28.00 to $20.00 in a report on Wednesday, August 7th. Six equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $25.56.

Insider Buying and Selling at ACADIA Pharmaceuticals

In other ACADIA Pharmaceuticals news, CEO Stephen Davis sold 31,747 shares of the firm's stock in a transaction on Monday, August 19th. The shares were sold at an average price of $15.28, for a total transaction of $485,094.16. Following the transaction, the chief executive officer now directly owns 186,555 shares of the company's stock, valued at approximately $2,850,560.40. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other ACADIA Pharmaceuticals news, COO Brendan Teehan sold 9,534 shares of the stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $15.28, for a total transaction of $145,679.52. Following the transaction, the chief operating officer now owns 52,177 shares of the company's stock, valued at $797,264.56. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Stephen Davis sold 31,747 shares of the business's stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $15.28, for a total value of $485,094.16. Following the sale, the chief executive officer now owns 186,555 shares of the company's stock, valued at $2,850,560.40. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 51,014 shares of company stock worth $779,494 over the last ninety days. Corporate insiders own 28.30% of the company's stock.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.